Global News Roundup: Q1 2023
Windrose Consulting Group, Global News Roundup: Q1 2023
Life science News from around the world
We are pleased to launch the next edition of our quarterly Windrose Consulting Group: Global News Roundup for Q1 2023
In this edition, we look at many key changes in the Global Life Sciences industry, such as: Major pharmaceutical companies are starting to deprioritize launches in Europe, particularly in Germany; Pharmaceutical disinvestment in the UK under intensified criticism of Voluntary Scheme for Branded Medicines and Access (VPAS); System Reforms Significantly Impact Commercial Opportunity for Pharmaceutical Products in Germany; The UK will soon look to the foreign leading regulatory authorities to accelerate marketing authorization; Spain will soon require manufacturers of all new medicines to submit economic evaluations; Universal Health Coverage for India was envisioned to be implemented by 2022, however the country is yet to ensure healthcare for all; plus more coverage from around the world.
Our contributing editors for this edition are:
William Noumba
Daisy Pharoah
Paige Stitzel
Jude Baroudi
Colin Banks
Amy Morgan
Windrose Consulting Group, Strategic guidance for Life Sciences.
Windrose Consulting Group is a privately-held global strategy firm that partners with life science companies to maximize the commercial value of their products, to help meet today’s most critical healthcare needs. We work across a broad range of products and disease areas. Our services that include product commercialization, pricing and market access and value communication. At Windrose, we’re committed to helping companies succeed in bringing innovations to market that enhance people’s lives. We work globally and have three offices, based in Philadelphia (US), London (UK) and Lucerne (Switzerland).